Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Candlesense
BIIB Clinical trials

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines –

Related Questions

How will the 3‑year open‑label extension data impact Biogen’s valuation and short‑term stock price movement? How does Zorevunersen’s efficacy and safety profile compare to existing Dravet syndrome therapies and other pipeline candidates? What is the expected regulatory timeline and potential market size if the data supports disease‑modifying claims?
Find similar articles on Candlesense globenewswire